David Haslam (GP and obesity specialist) - Revision history

Melissa Jones: adding categories

2011-02-03T16:04:09Z

adding categories

David: moved David Haslam - GP and obesity specialist to David Haslam (GP and obesity specialist)

2011-02-03T15:19:13Z

moved David Haslam - GP and obesity specialist to David Haslam (GP and obesity specialist)

Melissa Jones: moved David Haslam to David Haslam - GP and obesity specialist: disambiguation

2011-02-03T15:00:29Z

moved David Haslam to David Haslam - GP and obesity specialist: disambiguation

David: /* Debate over obesity drugs efficacy */

2010-11-13T08:58:57Z

Debate over obesity drugs efficacy

Melissa Jones: /* Affiliations */

2010-10-27T21:52:47Z

Affiliations

Melissa Jones: /* Affiliations */ ref added

2010-10-27T21:45:30Z

Affiliations: ref added

Melissa Jones: /* Affiliations */ ref added

2010-10-26T15:21:42Z

Affiliations: ref added

Melissa Jones: /* Debate over obesity drugs efficacy */

2010-10-12T15:20:40Z

Debate over obesity drugs efficacy

Melissa Jones: /* Debate over obesity drugs efficacy */

2010-10-07T23:21:25Z

Debate over obesity drugs efficacy

Melissa Jones at 23:20, 7 October 2010

2010-10-07T23:20:11Z

@@ Line 1: / Line 1: @@
 {{Template:Foodspin badge}}
-Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
+Dr '''David W Haslam''' is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>
 == Activities ==
@@ Line 43: / Line 43: @@
 <references/>
-[[Category:Health]]
+[[Category:Health|Haslam (GP and obesity specialist), David]][[Category:Healthcare Industry people|Haslam (GP and obesity specialist), David]]

@@ Line 16: / Line 16: @@
 :Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
-:Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.
+:Dr [[David Haslam]], chair of the [[National Obesity Forum]], slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.<ref>[http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4115938&c=2 . GPs divided on obesity drugs efficacy] Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007</ref>
 ==Affiliations==

@@ Line 30: / Line 30: @@
 *Bedfordshire and Hertfordshire Postgraduate Medical School - Staff <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 *[[PCOS UK]] (the clinical wing of Verity, the charity for sufferers of Polycystic Ovarian Syndrome) - executive director and member of the Executive Council <ref> [http://www.pcos-uk.org.uk/people.asp PCOS UK Executive Council ], accessed 6 October 2010. </ref>
-*[[76 Harley Street]] - leads its obesity services <ref>76 Harley Street [http://www.76harleystreet.com/sections/team/david_haslam Our Specialists: David Haslam],accessed 24 October 2010 </ref>
+*[[76 Harley Street]] - leads its obesity services (since at least 2008) <ref>76 Harley Street [http://www.76harleystreet.com/sections/team/david_haslam Our Specialists: David Haslam],accessed 24 October 2010 </ref>
 *[[Primary Care Cardiovascular Journal]], and the [[British Journal of Cardiology]] - member of both editorial boards <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 * [[iGlobalFitness]] - chairman, Medical Advisory Board, appointed 24 September 2010. iGlobalFitness describe themselves as 'the sustainable wellness experts'. <ref> [http://www.responsesource.com/releases/rel_display.php?relid=59486 iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board ], press release 24 September 2010, via Responsesource, [[Nilmot PR]], accessed 6 October 2010. </ref>

@@ Line 30: / Line 30: @@
 *Bedfordshire and Hertfordshire Postgraduate Medical School - Staff <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 *[[PCOS UK]] (the clinical wing of Verity, the charity for sufferers of Polycystic Ovarian Syndrome) - executive director and member of the Executive Council <ref> [http://www.pcos-uk.org.uk/people.asp PCOS UK Executive Council ], accessed 6 October 2010. </ref>
-*[[76 Harley Street]] - led its obesity services (dates needed)
+*[[76 Harley Street]] - leads its obesity services <ref>76 Harley Street [http://www.76harleystreet.com/sections/team/david_haslam Our Specialists: David Haslam],accessed 24 October 2010 </ref>
 *[[Primary Care Cardiovascular Journal]], and the [[British Journal of Cardiology]] - member of both editorial boards <ref>Bedfordshire and Hertfordshire Postgraduate Medical School, [http://www.bhpms.ac.uk/staff/david-haslam Staff Profile Dr David W Haslam, MB BS DGM], accessed 5 October 2010. </ref>
 * [[iGlobalFitness]] - chairman, Medical Advisory Board, appointed 24 September 2010. iGlobalFitness describe themselves as 'the sustainable wellness experts'. <ref> [http://www.responsesource.com/releases/rel_display.php?relid=59486 iGlobalFitness appoint Prof David Haslam and Dr Matthew Capehorn to Medical Advisory Board ], press release 24 September 2010, via Responsesource, [[Nilmot PR]], accessed 6 October 2010. </ref>

@@ Line 23: / Line 23: @@
 *[[National Obesity Forum]] - Chair
 *[[Counterweight]] - board member
-*[[Experts in Severe and Complex Obesity]]
+*[[Experts in Severe and Complex Obesity]] - a group set up to improve access and treatment for severe and complex obesity on the NHS <ref>Jane Elliot, [http://www.bbc.co.uk/news/health-10953629 BBC News], 14 August 2010, accessed 25 October 2010. </ref>
 *[[Robert Gordon University]], Aberdeen - Visiting Professor
 *[[Chester University]] - Visiting Professor <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>

← Older revision	Revision as of 15:19, 3 February 2011
(No difference)

← Older revision	Revision as of 15:00, 3 February 2011
(No difference)

@@ Line 6: / Line 6: @@
 === Debate over obesity drugs efficacy ===
-On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss.  Researchers had reviewed rom randomised controlled trials data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
+On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss.  Researchers had reviewed randomised controlled trials data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
 :Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.

← Older revision		Revision as of 23:20, 7 October 2010
Line 2:		Line 2:
	Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>		Dr David W Haslam is a general practitioner with a special interest in obesity and and cardiometabolic disease. He is a physician in Obesity Medicine at the [[Centre for Obesity Research]] at Luton & Dunstable Hospital, and Chair of the UK's [[National Obesity Forum]] (NOF). <ref> National Obesity Forum, [http://www.nationalobesityforum.org.uk/about-us/the-nof-trustees-mainmenu-159/122-dr-david-haslam.html Dr David Haslam], last accessed 6 October 2010. </ref>

		+	== Activities ==
		+
		+	=== Debate over obesity drugs efficacy ===
		+
		+	On 19 Nov 2007 a new study reported in the British Medical Journal (BMJ) showed that anti-obesity treatments frequently failed to promote weight loss. Researchers had reviewed data and concluded orlistat, sibutramine and rimonabant were of only ‘modest’ help in long-term weight loss.
		+
		+	:Average weight loss was less than 5%, below the thresholds for recommending a continuation of therapy by NICE. NICE advises anti-obesity drugs should be discontinued if patients have not lost at least 5% of their initial body weight after three months.
		+
		+	:Study leader Professor [[Gareth Williams]], professor of medicine at the [[University of Bristol]], said the studies showed the jury was still out on the long-term efficacy and safety of anti-obesity treatments. He added that they should not be given to patients who cannot lose weight through lifestyle changes alone.
		+
		+	:‘If patients can’t get on and take responsibility for their own lives, then flinging a pill at them is not going to do any useful work at all,’ he said.
		+
		+	:Professor Williams also warned of ‘insidious collateral damage’ if GSK was successful in its bid to make orlistat available over the counter in Europe.
		+
		+	:Dr David Haslam, chair of the National Obesity Forum, slammed the BMJ meta-analysis for being ‘full of errors’ and called it a ‘very bad’ paper. ‘Five percent weight loss is very clinically significant. What they are doing here is actually looking at average weight loss and some may not lose any weight but others may lose 10 or 20%.’Dr Haslam supported moves to make Orlistat available over the counter.
		+	<ref>[http://www.pulsetoday.co.uk/story.asp?sectioncode=23&storycode=4115938&c=2 . GPs divided on obesity drugs efficacy] Nigel Praities, 16 November 2007, PULSE,accessed 29 November 2007</ref>

	==Affiliations==		==Affiliations==